Axsome Total Current Assets vs Capital Surpluse Analysis

AXSM Stock

USD 128.33 1.24 0.98%

Axsome Therapeutics financial indicator trend analysis is way more than just evaluating Axsome Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Axsome Therapeutics is a good investment. Please check the relationship between Axsome Therapeutics Total Current Assets and its Capital Surpluse accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.

Total Current Assets vs Capital Surpluse

Total Current Assets vs Capital Surpluse Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Axsome Therapeutics Total Current Assets account and Capital Surpluse. At this time, the significance of the direction appears to have strong relationship.

The correlation between Axsome Therapeutics' Total Current Assets and Capital Surpluse is 0.76. Overlapping area represents the amount of variation of Total Current Assets that can explain the historical movement of Capital Surpluse in the same time period over historical financial statements of Axsome Therapeutics, assuming nothing else is changed. The correlation between historical values of Axsome Therapeutics' Total Current Assets and Capital Surpluse is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Assets of Axsome Therapeutics are associated (or correlated) with its Capital Surpluse. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Surpluse has no effect on the direction of Total Current Assets i.e., Axsome Therapeutics' Total Current Assets and Capital Surpluse go up and down completely randomly.

Correlation Coefficient

0.76

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.

Capital Surpluse

Most indicators from Axsome Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Axsome Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.At this time, Axsome Therapeutics' Selling General Administrative is very stable compared to the past year. As of the 27th of February 2025, Sales General And Administrative To Revenue is likely to grow to 1.82, while Issuance Of Capital Stock is likely to drop about 38.7 M.

	2022	2023	2024	2025 (projected)
Interest Expense	7.3M	6.5M	6.6M	3.3M
Depreciation And Amortization	5.6M	6.8M	7.9M	8.3M

Interest Expense Depreciation And Amortization

Axsome Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Other Liab	Net Tangible Assets	Current Deferred Revenue	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Non Current Liabilities Total
Total Assets		0.86	0.86	0.86	0.63	-0.74	-0.81	0.85	0.87	0.87	0.48	0.6	0.88	0.81	0.87	0.91	-0.18	0.63	0.45	0.38	0.62	0.87	0.85	0.54	0.85	0.87
Short Long Term Debt Total	0.86		0.97	0.97	0.41	-0.68	-0.98	0.96	0.92	0.92	0.62	0.76	0.95	0.99	0.99	0.97	-0.32	0.76	0.54	0.21	0.78	0.93	0.93	0.07	1.0	1.0
Other Current Liab	0.86	0.97		1.0	0.47	-0.55	-0.96	0.98	0.84	0.84	0.5	0.65	0.99	0.95	0.99	0.92	-0.24	0.66	0.48	0.14	0.69	0.92	0.96	0.15	0.96	0.98
Total Current Liabilities	0.86	0.97	1.0		0.44	-0.59	-0.97	0.99	0.86	0.86	0.54	0.68	0.99	0.95	0.99	0.93	-0.24	0.69	0.51	0.19	0.73	0.92	0.97	0.15	0.96	0.98
Total Stockholder Equity	0.63	0.41	0.47	0.44		-0.1	-0.31	0.38	0.28	0.28	-0.21	-0.05	0.53	0.34	0.45	0.37	0.05	-0.01	-0.16	-0.28	-0.11	0.6	0.53	0.69	0.41	0.46
Net Debt	-0.74	-0.68	-0.55	-0.59	-0.1		0.66	-0.62	-0.91	-0.91	-0.77	-0.8	-0.55	-0.64	-0.63	-0.82	0.33	-0.8	-0.64	-0.81	-0.85	-0.61	-0.54	-0.13	-0.68	-0.64
Retained Earnings	-0.81	-0.98	-0.96	-0.97	-0.31	0.66		-0.98	-0.91	-0.91	-0.69	-0.82	-0.95	-0.99	-0.98	-0.95	0.33	-0.82	-0.6	-0.24	-0.84	-0.92	-0.94	0.02	-0.98	-0.98
Accounts Payable	0.85	0.96	0.98	0.99	0.38	-0.62	-0.98		0.87	0.87	0.61	0.73	0.97	0.96	0.98	0.94	-0.3	0.74	0.56	0.25	0.79	0.92	0.97	0.1	0.96	0.97
Cash	0.87	0.92	0.84	0.86	0.28	-0.91	-0.91	0.87		1.0	0.75	0.85	0.83	0.9	0.89	0.98	-0.35	0.85	0.64	0.55	0.89	0.85	0.81	0.11	0.92	0.9
Cash And Short Term Investments	0.87	0.92	0.84	0.86	0.28	-0.91	-0.91	0.87	1.0		0.75	0.85	0.83	0.9	0.89	0.98	-0.35	0.85	0.64	0.55	0.89	0.85	0.81	0.11	0.92	0.9
Common Stock Total Equity	0.48	0.62	0.5	0.54	-0.21	-0.77	-0.69	0.61	0.75	0.75		0.95	0.51	0.64	0.57	0.69	-0.43	0.97	0.86	0.59	0.91	0.54	0.52	-0.23	0.62	0.57
Common Stock Shares Outstanding	0.6	0.76	0.65	0.68	-0.05	-0.8	-0.82	0.73	0.85	0.85	0.95		0.64	0.78	0.71	0.8	-0.35	0.98	0.74	0.49	0.93	0.7	0.66	-0.19	0.76	0.72
Other Current Assets	0.88	0.95	0.99	0.99	0.53	-0.55	-0.95	0.97	0.83	0.83	0.51	0.64		0.93	0.98	0.91	-0.26	0.67	0.52	0.13	0.67	0.93	0.97	0.22	0.95	0.97
Other Stockholder Equity	0.81	0.99	0.95	0.95	0.34	-0.64	-0.99	0.96	0.9	0.9	0.64	0.78	0.93		0.98	0.94	-0.36	0.77	0.54	0.19	0.81	0.93	0.94	-0.01	0.99	0.98
Total Liab	0.87	0.99	0.99	0.99	0.45	-0.63	-0.98	0.98	0.89	0.89	0.57	0.71	0.98	0.98		0.96	-0.27	0.72	0.51	0.19	0.75	0.93	0.96	0.12	0.99	1.0
Total Current Assets	0.91	0.97	0.92	0.93	0.37	-0.82	-0.95	0.94	0.98	0.98	0.69	0.8	0.91	0.94	0.96		-0.31	0.81	0.6	0.43	0.85	0.9	0.88	0.14	0.97	0.96
Short Term Debt	-0.18	-0.32	-0.24	-0.24	0.05	0.33	0.33	-0.3	-0.35	-0.35	-0.43	-0.35	-0.26	-0.36	-0.27	-0.31		-0.42	-0.5	-0.22	-0.43	-0.31	-0.28	0.22	-0.33	-0.29
Common Stock	0.63	0.76	0.66	0.69	-0.01	-0.8	-0.82	0.74	0.85	0.85	0.97	0.98	0.67	0.77	0.72	0.81	-0.42		0.82	0.51	0.91	0.7	0.67	-0.13	0.76	0.73
Other Liab	0.45	0.54	0.48	0.51	-0.16	-0.64	-0.6	0.56	0.64	0.64	0.86	0.74	0.52	0.54	0.51	0.6	-0.5	0.82		0.53	0.77	0.46	0.47	-0.13	0.53	0.51
Net Tangible Assets	0.38	0.21	0.14	0.19	-0.28	-0.81	-0.24	0.25	0.55	0.55	0.59	0.49	0.13	0.19	0.19	0.43	-0.22	0.51	0.53		0.63	0.12	0.13	0.11	0.21	0.18
Current Deferred Revenue	0.62	0.78	0.69	0.73	-0.11	-0.85	-0.84	0.79	0.89	0.89	0.91	0.93	0.67	0.81	0.75	0.85	-0.43	0.91	0.77	0.63		0.69	0.69	-0.21	0.79	0.74
Non Current Assets Total	0.87	0.93	0.92	0.92	0.6	-0.61	-0.92	0.92	0.85	0.85	0.54	0.7	0.93	0.93	0.93	0.9	-0.31	0.7	0.46	0.12	0.69		0.97	0.2	0.94	0.94
Non Currrent Assets Other	0.85	0.93	0.96	0.97	0.53	-0.54	-0.94	0.97	0.81	0.81	0.52	0.66	0.97	0.94	0.96	0.88	-0.28	0.67	0.47	0.13	0.69	0.97		0.19	0.93	0.94
Other Assets	0.54	0.07	0.15	0.15	0.69	-0.13	0.02	0.1	0.11	0.11	-0.23	-0.19	0.22	-0.01	0.12	0.14	0.22	-0.13	-0.13	0.11	-0.21	0.2	0.19		0.06	0.11
Long Term Debt	0.85	1.0	0.96	0.96	0.41	-0.68	-0.98	0.96	0.92	0.92	0.62	0.76	0.95	0.99	0.99	0.97	-0.33	0.76	0.53	0.21	0.79	0.94	0.93	0.06		1.0
Non Current Liabilities Total	0.87	1.0	0.98	0.98	0.46	-0.64	-0.98	0.97	0.9	0.9	0.57	0.72	0.97	0.98	1.0	0.96	-0.29	0.73	0.51	0.18	0.74	0.94	0.94	0.11	1.0

Click cells to compare fundamentals

Axsome Therapeutics Account Relationship Matchups

Axsome Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	186.1M	(338.4M)	331.5M	588.2M	568.5M	596.9M
Short Long Term Debt Total	50.1M	49.7M	94.7M	186.4M	191.5M	201.1M
Other Current Liab	8.7M	9.3M	57.5M	96.9M	155.3M	163.1M
Total Current Liabilities	23.4M	23.1M	96.6M	138.9M	230.1M	241.6M
Total Stockholder Equity	(278.8M)	(409.2M)	109.6M	191.0M	57.0M	59.9M
Net Debt	(133.8M)	(36.8M)	(106.2M)	(199.8M)	(123.8M)	(117.6M)
Retained Earnings	(278.8M)	(409.2M)	(596.3M)	(835.6M)	(1.1B)	(1.1B)
Accounts Payable	13.5M	13.1M	38.6M	40.7M	72.0M	75.6M
Cash	183.9M	86.5M	200.8M	386.2M	315.4M	331.1M
Cash And Short Term Investments	183.9M	86.5M	200.8M	386.2M	315.4M	331.1M
Common Stock Total Equity	3.0K	3.7K	3.7K	3.8K	4.3K	2.7K
Common Stock Shares Outstanding	37.2M	37.6M	40.7M	45.4M	47.9M	32.0M
Liabilities And Stockholders Equity	(206.5M)	(338.4M)	331.5M	588.2M	568.5M	596.9M
Other Current Assets	148.4K	45.3K	5.6M	8.1M	12.0M	12.6M
Other Stockholder Equity	392.6M	424.8M	705.9M	1.0B	1.2B	1.2B
Total Liab	72.3M	70.8M	221.9M	397.3M	511.5M	537.1M
Total Current Assets	184.0M	86.5M	245.6M	504.3M	485.1M	509.3M
Short Term Debt	1.2M	620.7K	425K	1.3M	1.8M	1.4M
Common Stock	3.7K	3.8K	4.4K	5K	5.8K	3.4K
Net Tangible Assets	178.7M	113.8M	15.6M	39.6M	45.5M	52.6M
Non Current Assets Total	2.1M	1.3M	85.8M	84.0M	83.4M	87.6M
Non Currrent Assets Other	317.4K	322.9K	14.7M	11.0M	19.1M	20.1M
Other Assets	139.9K	2.1M	(426.1M)	14.7M	13.2M	13.9M
Long Term Debt	48.3M	49.1M	94.3M	178.1M	180.7M	189.7M
Non Current Liabilities Total	48.9M	49.1M	125.4M	258.4M	281.4M	295.4M
Property Plant And Equipment Net	1.8M	944.0K	1.1M	7.6M	5.4M	5.7M
Property Plant And Equipment Gross	1.8M	944.0K	1.1M	7.6M	6.0M	6.3M
Property Plant Equipment	30.6K	52.6K	283.8K	1.1M	1.3M	1.4M
Retained Earnings Total Equity	(107.6M)	(175.9M)	(278.8M)	(409.2M)	(368.3M)	(349.9M)
Long Term Debt Total	3.6M	17.3M	48.3M	49.1M	56.5M	59.3M
Capital Surpluse	108.5M	354.6M	392.6M	424.8M	488.5M	264.6M
Net Invested Capital	162.1M	64.7M	203.8M	369.0M	237.7M	174.7M
Net Working Capital	160.6M	63.5M	149.1M	365.4M	255.0M	167.3M
Capital Stock	3.7K	3.8K	4.4K	5K	5.8K	4.5K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Axsome Therapeutics is a strong investment it is important to analyze Axsome Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Axsome Therapeutics' future performance. For an informed investment choice regarding Axsome Stock, refer to the following important reports:

How To Invest In Axsome

Details

Is Axsome Stock a good investment?

Details

What is Axsome Therapeutics' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.

You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(6.04)

Revenue Per Share

8.05

Quarterly Revenue Growth

0.66

Return On Assets

(0.27)

Return On Equity

(2.32)

The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Axsome Total Current Assets vs Capital Surpluse Analysis

Total Current Assets vs Capital Surpluse

Total Current Assets vs Capital Surpluse Correlation Analysis

Correlation Coefficient

Total Current Assets

Capital Surpluse

Axsome Therapeutics fundamental ratios Correlations

Axsome Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Axsome Therapeutics fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Long Term Debt	+ 1.0	Short Long Term Debt Total
Non Current Liabilities Total	+ 1.0	Short Long Term Debt Total
Total Current Liabilities	+ 1.0	Other Current Liab
Cash And Short Term Investments	+ 1.0	Cash
Non Current Liabilities Total	+ 1.0	Total Liab
Non Current Liabilities Total	+ 1.0	Long Term Debt

Other Stockholder Equity	- 0.99	Retained Earnings
Non Current Liabilities Total	- 0.98	Retained Earnings
Long Term Debt	- 0.98	Retained Earnings
Total Liab	- 0.98	Retained Earnings
Accounts Payable	- 0.98	Retained Earnings
Retained Earnings	- 0.98	Short Long Term Debt Total